U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07359963) titled 'Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy' on Jan. 13.
Brief Summary: This study is a prospective, single-arm, dose-escalation exploratory clinical trial to investigate the safety, tolerability and preliminary efficacy of REGEND007 stem cell preparation administered by intravenous infusion in the treatment of idiopathic pulmonary fibrosis (IPF), with a follow-up period of 12 weeks.
Study Start Date: Feb. 15
Study Type: INTERVENTIONAL
Condition:
Idiopathic Pulmonary Fibrosis (IPF)
Intervention:
BIOLOGICAL: REGEND007 Cell Therapy
This study's intravenous infusion dose escalation protocol is base...